Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

<p>amino acid sequences of mAbs in this study</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Yuncheng Bei (16546095) (author)
Бусад зохиолчид:	Jian He (16546098) (author), Xuhui Dong (16546101) (author), Yuxin Wang (16546104) (author), Sijie Wang (16546107) (author), Wan Guo (16546110) (author), Chengjie Cai (16546113) (author), Zhiye Xu (16546116) (author), Jia Wei (11469308) (author), Baorui Liu (15134681) (author), Nan Zhang (16546119) (author), Pingping Shen (16546122) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Computational Methods Database resources Drug Targets Cell surface receptor drug targets Preclinical Models Xenograft models
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
-н: Yuncheng Bei (16546095)
Хэвлэсэн: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
-н: Sheheryar Kabraji (15050565)
Хэвлэсэн: (2025)

Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
-н: Amr El Zawily (14851115)
Хэвлэсэн: (2025)

Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
-н: Amr El Zawily (14851115)
Хэвлэсэн: (2025)

Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
-н: Amr El Zawily (14851115)
Хэвлэсэн: (2025)

Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
-н: Amr El Zawily (14851115)
Хэвлэсэн: (2025)

Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
-н: Amr El Zawily (14851115)
Хэвлэсэн: (2025)

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
-н: Amr El Zawily (14851115)
Хэвлэсэн: (2025)

Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
-н: Amr El Zawily (14851115)
Хэвлэсэн: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
-н: Martina S.J. McDermott (15206951)
Хэвлэсэн: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
-н: Santiago Duro-Sánchez (14959182)
Хэвлэсэн: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
-н: Erwin Tomasich (15052256)
Хэвлэсэн: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
-н: Xiaoqing Cheng (16918496)
Хэвлэсэн: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
-н: Niklas Klümper (15048887)
Хэвлэсэн: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
-н: Niklas Klümper (15048887)
Хэвлэсэн: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
-н: Yuanqing Ma (15052437)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_jatk60ejbfcnhsco9khtjc5v2q